MPP sublicenses sutezolid, an investigational drug for TB treatment, paving the way for clinical development

The Medicines Patent Pool (MPP) and the Bill & Melinda Gates Medical Research Institute signed an agreement to advance the development of investigational sutezolid-containing TB drug regimens, especially for low- and middle-income countries, where most people with TB live. The drug candidate sutezolid, in combination with other drugs, could potentially be used as an all-oral, shortened regimen for all forms of TB, including multidrug-resistant TB.